Title:Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis
VOLUME: 23 ISSUE: 7
Author(s):Ekaterina A. Ivanova, Veronika A. Myasoedova*, Alexandra A. Melnichenko and Alexander N. Orekhov
Affiliation:Department of Development and Regeneration, Katholieke Universiteit Leuven (KU Leuven), Leuven, 3000, Unit of Atherosclerosis Prevention, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, 20138, Milan, Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Russian Academy of Sciences, Moscow 125315, Institute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow 121609
Keywords:Peroxisome proliferation-activated receptor gamma (PPARγ), cardiovascular disorders, cardiovascular surgery,
atherosclerosis.
Abstract:Peroxisome proliferation-activated receptors (PPARs) are ligand-activated transcription factors that
mainly regulate genes responsible for fatty acid (FA) and energy metabolism. There are three members of the
PPAR family, PPAR-α, PPAR- β/δ and PPAR-γ. All three isoforms have therapeutic potential for treatment of
cardiovascular disorders, and PPAR agonists are currently being actively studied in pre-clinical and clinical trials.
PPAR γ agonists, main tissue expressing isoform, have potential to influence on inflammation processes, reduce
oxidative stress, improve endothelial function and plays an important role in lipid metabolism. PPAR-γ agonists
are used as insulin sensitizers for treatment of diabetes; however, there is accumulating evidence that their clinical
application can be broadened. The wide spectrum of PPAR-γ activation effects may be beneficial for treatment of
various cardiovascular conditions as atherosclerosis, hypertension and aortic aneurysm, including surgical
interventions. In this Review we will discuss the implication of PPAR-γ in the cardiovascular system and
potential role of PPAR-γ agonists in treatment of conditions associated with high cardiovascular risks.
